Ixekizumab

Introduction Overview

Generic Name

ixekizumab

Brand Name

Taltz

Dosage Form

Solution for subcutaneous injection: Autoinjector (80 mg/mL), Prefilled Syringe (20 mg/0.25 mL, 40 mg/0.5 mL, 80 mg/mL)

Drug Class

Interleukin inhibitors (specifically interleukin-17A inhibitor)

Pharmacokinetics

Absorption:
Ixekizumab is administered subcutaneously, allowing absorption through the subcutaneous tissue into systemic circulation. Following administration, peak serum concentrations typically occur within a few days, generally around 4 to 7 days post-dose, reflecting moderate bioavailability typical of monoclonal antibodies administered subcutaneously. Absorption kinetics may be influenced by injection site and local tissue perfusion. No significant impairment of absorption has been reported in patients with psoriasis or psoriatic arthritis. Clinical trials have demonstrated that the dosing interval of every 2 to 4 weeks maintains therapeutic serum concentrations.

Distribution:
Once absorbed, ixekizumab distributes primarily within vascular and interstitial compartments. As a large monoclonal antibody (approximately 150 kDa), it has limited volume of distribution, typically close to plasma and extracellular fluid volume. Ixekizumab does not significantly penetrate intracellular compartments due to its molecular size. Data indicate limited central nervous system penetration, consistent with its molecular properties. Binding to the target interleukin-17A cytokine occurs in the extracellular space, leading to modulation of immune responses.

Metabolism:
Ixekizumab, like other monoclonal antibodies, undergoes catabolic metabolism via proteolytic enzymes ubiquitous in reticuloendothelial and other tissues. It is degraded into small peptides and amino acids through non-specific pathways, without involvement of hepatic cytochrome P450 enzymes or specific organ metabolism. Therefore, hepatic or renal impairment is not expected to significantly affect ixekizumab metabolism or elimination.

Elimination:
The elimination of ixekizumab follows typical monoclonal antibody kinetics, with a half-life averaging approximately 13 days, supporting dosing every 4 weeks after initial loading doses. Clearance occurs predominantly through catabolism by reticuloendothelial cells. Due to its large molecular size, renal excretion is negligible. No accumulation has been observed with repeated dosing at recommended intervals. Clearance may be influenced by immunogenicity or formation of anti-drug antibodies, although clinical significance remains low in terms of efficacy reduction or adverse effects.

Dosage Forms

**Available Dosage Forms:**
- Autoinjector: 80 mg/mL single-dose prefilled autoinjector
- Prefilled Syringe: single-dose prefilled syringes available in 20 mg/0.25 mL, 40 mg/0.5 mL, and 80 mg/mL concentrations

**Dosages for Adults and Adolescents:**
- *Plaque Psoriasis in Adults:* Initial dose of 160 mg (two 80 mg injections) subcutaneously at Week 0; then 80 mg at Weeks 2, 4, 6, 8, 10, and 12; followed by 80 mg every 4 weeks as maintenance.
- *Plaque Psoriasis in Pediatric Patients (6 to <18 years):* For weight < 25 kg: 40 mg subcutaneously at Week 0, then 20 mg every 4 weeks; for weight 25–50 kg: 80 mg at Week 0, then 40 mg every 4 weeks; for weight > 50 kg: 160 mg (two 80 mg injections) at Week 0, then 80 mg every 4 weeks.
- *Psoriatic Arthritis in Adults:* 160 mg at Week 0 (two injections), then 80 mg every 4 weeks; dosing for patients with moderate-to-severe plaque psoriasis follows plaque psoriasis regimen.
- *Ankylosing Spondylitis in Adults:* 160 mg at Week 0 (two injections), then 80 mg every 4 weeks.
- *Non-radiographic Axial Spondyloarthritis in Adults:* 160 mg at Week 0 (two injections), then 80 mg every 4 weeks.

**Specific Patient Populations:**
- Pediatric use is supported for moderate-to-severe plaque psoriasis in patients as young as 6 years, with dosing adjusted by weight.
- No specific dose adjustments are required for renal or hepatic impairment due to metabolism and clearance pathways.
- Combination use with conventional disease-modifying antirheumatic drugs (cDMARDs) such as methotrexate is permissible for psoriatic arthritis.
- Administration should avoid injection into areas of active skin disease, bruises, or scars to maintain efficacy and reduce local reactions.
- Self-administration via autoinjector or prefilled syringe is possible following appropriate training.
- Injection sites include anterior thighs, abdomen (avoiding area around navel), and if given by caregiver, the upper arm is acceptable.

Clinicians should follow initial loading and maintenance dosing schedules specific to the indication, with monitoring for clinical response and adverse effects guiding ongoing therapy.

Mechanism Of Action

Ixekizumab is a high-affinity, humanized monoclonal antibody that selectively targets and neutralizes interleukin-17A (IL-17A), a proinflammatory cytokine central to the pathogenesis of several autoimmune and inflammatory diseases. IL-17A is produced predominantly by Th17 cells, a subset of CD4+ T helper lymphocytes, and orchestrates inflammatory processes by inducing expression of downstream cytokines, chemokines, and mediators that promote inflammation, tissue remodeling, and recruitment of neutrophils.

By binding specifically to IL-17A, ixekizumab prevents its interaction with the IL-17 receptor complex expressed on epithelial, endothelial, and fibroblast cells. This blockade inhibits IL-17A-mediated signaling pathways, thereby reducing the production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), and various chemokines that contribute to inflammatory cell recruitment and activation.

Clinically, this mechanism results in decreased inflammation in skin lesions characteristic of plaque psoriasis and reduced synovial inflammation and joint damage in psoriatic arthritis and axial spondyloarthritis conditions, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. The inhibition of IL-17A is particularly effective in disrupting the IL-23/Th17 axis implicated in chronic inflammation of these diseases.

Comparatively, ixekizumab operates similarly to other IL-17A inhibitors such as secukinumab but differs from tumor necrosis factor inhibitors (e.g., adalimumab) in its targeted blockade of a cytokine more specifically implicated in neutrophil-mediated inflammation. Clinical studies have demonstrated rapid onset of action and high efficacy in skin clearance and joint symptom improvement with ixekizumab, underscoring the critical role of IL-17A in disease pathophysiology. Further research continues to elucidate its long-term immunomodulatory effects and safety profile.

Pharmacological Actions

Selective inhibition of interleukin-17A (IL-17A), a key pro-inflammatory cytokine.
Modulation of Th17 cell-mediated immune responses involved in autoimmune pathology.
Reduction of inflammatory cytokine and chemokine production in skin and joint tissues.
Inhibition of neutrophil recruitment and activation at sites of inflammation.
Suppression of keratinocyte hyperproliferation associated with psoriatic plaques.
Attenuation of synovial inflammation and prevention of joint damage in psoriatic arthritis.
Reduction of spinal inflammation in ankylosing spondylitis and axial spondyloarthritis.
Decreased expression of downstream pro-inflammatory mediators such as TNF-α and IL-6.
Rapid onset of clinical effect due to targeted cytokine blockade.
Potential modulation of innate immune activation contributing to disease symptomatology.
Minimal off-target effects due to high specificity for IL-17A monoclonal antibody binding.
Improvement of both cutaneous and musculoskeletal symptoms through systemic immunomodulation.

Therapeutic Or Clinical Uses

Treatment of moderate to severe plaque psoriasis in adult and pediatric patients (6 years and older) requiring systemic therapy or phototherapy.
Management of active psoriatic arthritis in adult patients, including in combination with conventional DMARDs.
Therapy for active ankylosing spondylitis in adults to reduce spinal inflammation and improve mobility.
Treatment of non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adult patients.
Reduction of erythema, scaling, and skin thickness characteristic of psoriatic skin lesions.
Alleviation of joint pain, swelling, and stiffness associated with psoriatic arthritis and spondyloarthropathies.
Adjunct therapy in autoimmune diseases characterized by IL-17A mediated inflammation.
Maintenance therapy following initial induction dosing to sustain clinical remission or low disease activity.
Treatment of patients intolerant or refractory to other systemic or biologic therapies.
Option for self-administration to improve treatment adherence and patient convenience.
Management of chronic inflammatory conditions to prevent disease progression and complications.
Therapeutic intervention to improve quality of life and functional outcomes in autoimmune disease patients.
Use in patients with contraindications to TNF inhibitors or other biologics targeting different immune pathways.
Treatment option with a well-characterized safety and efficacy profile supported by clinical trials.
FDA-approved indications reflecting broad utility across multiple autoimmune inflammatory indications.

Side Or Adverse Effects

Injection site reactions, including pain, redness, swelling, or itching at the injection site.
Upper respiratory tract infections such as nasopharyngitis, common cold symptoms including sneezing, sore throat, and stuffy nose.
Nausea as a gastrointestinal adverse effect.
Increased risk of infections, including serious or opportunistic infections due to immune modulation.
Conjunctivitis and other ocular infections presenting as eye irritation or redness.
Hypersensitivity reactions ranging from mild rash to severe anaphylaxis requiring emergency intervention.
Potential exacerbation or new onset of inflammatory bowel disease (Crohn’s disease or ulcerative colitis) during therapy.
Serious fungal infections presenting as skin rashes or mucosal candidiasis, requiring prompt management.
Fever, chills, muscle pain, and weight loss suggestive of systemic infection or immune adverse response.
Diarrhea, which can be bloody or accompanied by abdominal cramps signaling gastrointestinal inflammation.
Oral thrush or white patches in mouth and throat due to yeast infections.
Signs of urinary tract infections including increased urination, dysuria, or burning sensation.
Respiratory symptoms such as cough with pink or red sputum and shortness of breath indicating possible pulmonary infection.
Potential for development of anti-drug antibodies leading to altered efficacy or allergic reactions.
Rare, but possible, systemic hypersensitivity necessitating immediate discontinuation and treatment.

Precautions

Screen patients prior to initiation for active or latent tuberculosis, and monitor for signs of infection during therapy.
Avoid use in patients with known hypersensitivity to ixekizumab or any component of the formulation.
Advise patients to avoid live vaccines during treatment with Taltz due to impaired immune response.
Closely monitor patients with pre-existing inflammatory bowel disease, as treatment may exacerbate symptoms.
Evaluate patients for risk factors of infections, especially those with immunocompromised states or comorbidities.
Counsel patients appropriately on reporting symptoms of infection including fever, cough, or chills promptly.
Use caution when combining Taltz with other immunosuppressive agents to limit cumulative immune suppression.
Regularly assess immunization status and update vaccinations prior to initiation whenever possible.
Pregnancy and breastfeeding: Use only if clearly needed; limited data available, enroll in pregnancy registry if applicable.
Educate patients on proper injection technique and site rotation to minimize local adverse reactions.
Advise against sharing medication devices to avoid cross-contamination and infection transmission.
Monitor for allergic reactions, particularly after initial doses, with readiness to intervene as necessary.
Consider the risk-benefit balance in elderly patients and those with comorbid conditions.
Provide guidance on storage conditions to maintain medication stability and efficacy.
Ensure patient adherence to the prescribed dosing schedule for optimal therapeutic outcomes.

Warnings

Serious infections: Patients are at increased risk of infections including tuberculosis, bacterial, viral, or fungal infections; prompt evaluation is required if symptoms occur.
Hypersensitivity reactions including anaphylaxis may occur; discontinue treatment immediately if severe reactions arise.
Live vaccines should not be administered during Taltz therapy due to immunosuppression and potential vaccine failure.
Exacerbation or new onset of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; monitor patients with history or risk factors carefully.
Potential immunogenicity with formation of anti-drug antibodies that may reduce effectiveness or cause reactions.
Infections may present atypically; clinicians should maintain high suspicion and monitor patients closely.
Discontinuation of therapy is advised in the event of active serious infections until resolution.
Use during pregnancy only if clearly necessary; potential risks are unknown, and limited data exist.
Hospitalization or invasive procedures may require temporary interruption of therapy to reduce infection risk.
Avoid concomitant use with other biologics targeting the immune system due to increased immunosuppression.
Monitor patients for potential malignancy development, as with other immunomodulatory agents, although direct causality is not established.
Patients should be advised to seek medical attention for any new or worsening signs of infection or allergic reaction.
Insufficient data for use in patients with severe immunodeficiency states; use caution and clinical judgment.
Immediate medical attention should be sought for signs of anaphylaxis, including difficulty breathing, swelling, or rash.
Maintain vigilance for neurological symptoms suggestive of demyelinating disease, although rare.

Contraindication

Known hypersensitivity or allergy to ixekizumab or any component of the Taltz formulation.
History of serious hypersensitivity reactions to Taltz including anaphylaxis.
Active serious infections including tuberculosis, sepsis, or opportunistic infections at the time of initiation.
Concurrent administration of live vaccines during treatment course.
Caution advised in patients with pre-existing moderate to severe inflammatory bowel disease presenting with active symptoms.
Use contraindicated in individuals with known immunodeficiency states where further immune suppression is unsafe.
Known hypersensitivity to excipients such as polysorbate 80 or sucrose if relevant clinical allergy documented.
Patients who have experienced severe allergic reactions on prior biologic treatments may require alternative therapies.
Any condition where intense immune blockade would pose undue risk outweighing clinical benefits.
Pregnancy and breastfeeding use contraindicated unless benefits justify potential risks due to insufficient data.
Patients with uncontrolled or severe infections unresponsive to antimicrobial therapy.
Known hypersensitivity to similar interleukin-17 inhibitors may require cautious approach or contraindication.
Cases of acute severe infections requiring emergent intervention warrant postponement of therapy.
Contraindication includes patients with hypersensitivity to previous humanized monoclonal antibodies if cross-reactivity is suspected.
Patients unable to self-administer or those with poor adherence without proper caregiver support may not be considered.

Drug Interactions

Concomitant use with carbamazepine may alter immune response or clearance; monitor clinical response carefully.
Cyclosporine, an immunosuppressant, may increase infection risk when combined with Taltz; closely monitor for infections.
Quinidine, used for arrhythmias, may have theoretical pharmacodynamic interactions necessitating clinical monitoring.
Sirolimus, an mTOR inhibitor, may synergize immunosuppressive effects raising infection risk with concurrent use.
Tacrolimus co-administration with Taltz requires vigilance for enhanced immunosuppression and toxicity.
Warfarin use alongside Taltz mandates careful monitoring of anticoagulation parameters due to potential indirect interactions.
Live vaccines should not be administered concomitantly or shortly after Taltz treatment due to impaired vaccine efficacy and safety concerns.
Other biologic immunomodulators targeting different cytokines (e.g., TNF inhibitors) may increase immunosuppression if combined.
Corticosteroids administered with Taltz could potentiate immunosuppression, requiring assessment of infection risk.
Potential impact on cytochrome P450 enzymes is minimal due to monoclonal antibody metabolism; drug interactions mediated via CYP enzymes are unlikely.
Concomitant use of immunosuppressive herbal products or supplements should be disclosed to healthcare professionals.
No significant pharmacokinetic interactions identified with commonly prescribed medications in clinical use.
Patients should inform all healthcare providers about use of Taltz to avoid contraindicated or interacting medications.
Drug interaction databases and clinical resources should be consulted prior to administering novel therapies concurrently.
Special caution advised when combining with therapies that compromise immune defense to prevent opportunistic infections.

Preparations Of The Drug

Taltz 80 mg/mL single-dose prefilled autoinjector for subcutaneous use.
Taltz prefilled syringe containing 20 mg/0.25 mL solution for subcutaneous injection.
Taltz prefilled syringe containing 40 mg/0.5 mL solution for subcutaneous injection.
Taltz prefilled syringe containing 80 mg/mL solution for subcutaneous injection.
Injection solution is clear to slightly yellow with no visible particles.
Supplied in individual packages with instructions for use and storage guidelines.
Does not contain natural rubber latex, minimizing allergic risk.
Contains inactive ingredients: polysorbate 80, sucrose, water for injection, and sodium hydroxide for pH adjustment.
Available in multi-pack options (e.g., 2 or 3 autoinjectors) with specific storage instructions.
Stored refrigerated between 2°C to 8°C (36°F to 46°F); may be kept at room temperature up to 30°C (86°F) for maximum 5 days prior to use.
Do not freeze or shake; discard if frozen or if solution is cloudy or contains particulate matter.
Single-use only; autoinjectors and syringes are disposable and should be discarded in appropriate sharps containers.
Detailed patient instructions and training materials are provided to ensure proper administration.
Packaging includes labeling with dose strength, expiration dates, and lot numbers for traceability.
Medication should be protected from light and stored in original carton until use to maintain stability.